Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: Incidence, effects on aPTT, and clinical relevance

Blood

Volumn 96, Issue 7, 2000, Pages 2373-2378

  Eichler, P ^a   Friesen, H J ^a   Lubenow, N ^a   Jaeger, B ^a   Greinacher, A ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DESULFATOHIRUDIN; HEPARIN; HIRUDIN; LEPIRUDIN;

ADULT; ANTIBODY TITER; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 0034307370     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.7.2373.h8002373_2373_2378     Document Type: Article

References (36)

1. The development of hirudin as an antithrombotic drug
2. Prevention of deep-vein thrombosis after total hip replacement: Direct thrombin inhibition with recombinant hirudin CGP 39393
3. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia
4. Antigen generation in heparin-associated thrombocytopenia: The nonimmunologic and the immunologic type are closely linked in their pathogenesis
5. Heparin-associated thrombocytopenia: The antibody is not heparin specific
6. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia
7. Heparin associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen
8. Heparininduced thrombocytopenia: Laboratory studies
9. Heparin-induced thrombocytopenia: Mechanism of interaction of the heparin-dependent antibody with platelets
10. Immune endothelial-cell injury in heparin-associated thrombocytopenia
11. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
12. Clinical trials of recombinant hirudin in acute coronary syndromes
13. Hirudin in acute myocardial infarction: Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial
14. Recombinant hirudin in patients with chronic, stable coronary artery disease: Safety, half-life, and effect on coagulation parameters
15. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: A multicentre prospective dose-ranging randomized trial
16. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT III) study
17. Safety and efficacy of recombinant hirudin (CGP 39393) versus heparin in patients with stable angina undergoing coronary angioplasty
18. Recombinant hirudin for unstable angina pectoris: A multicenter randomized angiographic trial
19. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia
20. First workshop for detection of heparin-induced antibodies: Validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA
21. Recombinant hirudin (Lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia - A prospective study
22. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia
23. Development, characterization and application of antihirudin mouse monoclonal antibodies
24. Determination of thrombin-hirudin complex in plasma with an enzyme-linked immunosorbent assay
25. Studies for revealing a possible sensitization to hirudin after repeated intravenous injections in baboons
26. Pharmacokinetics, effect on clotting tests and assessment of the immunogenic potential of hirudin after a single subcutaneous or intravenous bolus administration in man
27. Weak allergenicity of recombinant hirudin CGP 39393 (REVASC) in immunocompetent volunteers: The European Hirudin in Thrombosis Group (HIT Group)
28. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia
29. Immunologic response to recombinant hirudin in HIT type II patients during long term treatment
30. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin
31. Pharmacokinetics of hirudin
32. Immunoassays in monitoring biotechnological drugs
33. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers
34. Potent anti-thrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin
35. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement